Sorafenib: from literature to clinical practice.
Author(s): Di Marco V(1), De Vita F, Koskinas J, Semela D, Toniutto P, Verslype C.
Affiliation(s): Author information:
(1)Sezione di Gastroenterologia & Epatologia, Dipartimento Biomedico di Medicina
Interna e Specialistica, University of Palermo, Palermo, Italy.
vito.dimarco@unipa.it
Publication date & source: 2013, Ann Oncol. , 24 Suppl 2:ii30-7
Sorafenib is considered the standard systemic therapy for hepatocellular
carcinoma (HCC), in patients with well-preserved liver function (Child-Pugh A
class) and advanced-stage HCC (BCLC-C) or in patients with HCC progressing after
locoregional therapies, with a high grade of recommendation. The approval of
sorafenib for this indication was grounded on the efficacy and the safety results
reported by two international randomized, controlled trials, the SHARP and the
Asia-Pacific studies. In addition, the efficacy and the safety of sorafenib in
clinical practice are addressed by several field-practice experiences, including
the multinational GIDEON study and the SOFIA study. Finally, further research on
sorafenib is ongoing to optimize the use of this molecule. This review aims to
provide an overview of the most relevant clinical data on the efficacy and the
safety of sorafenib in patients with HCC.
|